Skip to content
DataLookout
Menu

NCT05247268

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 15 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 2 of 7 entries
    • Site details revised
    • Publications: details revised at 22 of 22 entries
  2. Notable Primary completion date: Mar 10, 2025 to Mar 10, 2027
    • Study completion date: Mar 10, 2025 to Sep 10, 2027
    v6
  3. Minor Site details revisedv5
  4. Notable Primary completion date: Mar 10, 2024 to Mar 10, 2025v4
  5. Minor Primary completion date: Mar 1, 2024 to Mar 10, 2024
    • Study completion date: Mar 1, 2025 to Mar 10, 2025
    v3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 1, 2022 to Mar 11, 2022
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Complete response rates within 16 weeks of treatment
Timeframe: From date of treatment initiation until the date of CR, assessed up to 16 weeks.

Secondary (7)

Complete response rates within 28 weeks of treatment
Time to achieve complete response
Adverse events
Quality of life during the treatment accessed by WHOQOL-BREF
Relapse rates
Show 2 moreShow less
Change of AMH (anti-mullerian hormone ) serum level
The rates of fertility outcomes

Arms and interventions

GnRHa+letrozoleExperimental

Patients will be stratified into BMI≥28kg/m2 group and BMI\<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI\<28kg/m2 group will be randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group. Patients who will be assigned to GnRHa+letrozole group will receive triprorelin acetate (intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses) plus letrozole (2.5mg oral daily and no more than 24 weeks). Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.

MA/MPAActive comparator

Patients will be stratified into BMI≥28kg/m2 group and BMI\<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI\<28kg/m2 group were randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group.Patients assigned to MA/MPA group will receive MA/MPA (160 mg oral MA daily or 500 mg oral MPA daily).Then every 3 months, an hysteroscopy will be used to evaluate the endometrial condition, and the findings will be recorded.

Drugs: Megestrol Acetate 160 MG Oral Tablet, Medroxyprogesterone Acetate 500 MG, Triprorelin Acetate, Letrozole 2.5mg

Sites

1 site in 1 country

  • Obstetrics and Gynecology Hospital, Fudan UniversityShanghai, China